Clinical trials
Relapse clinical trials
Below are recruiting relapse clinical trials, each written for real people, not researchers. We’re tracking 892 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06453044RecruitingPhase 2
Study of two drugs for follicular lymphoma that came back
This study tests a combination of two targeted drugs (mosunetuzumab and polatuzumab vedotin) for people with follicular lymphoma that has come back or not responded to previous treatment. The goal is to see if this two-drug approach can help shrink tumors and control the disease.
Duarte, CaliforniaAges 18 years+ - NCT06458439RecruitingPhase 2
Epcoritamab with CAR T cells for large B-cell lymphoma
This trial tests a combination of two immune therapies—epcoritamab (a bispecific antibody) and CAR T cells—for people with large B-cell lymphoma whose cancer didn't respond to first treatment. The goal is to see if this combination works better than CAR T cells alone.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06452732Recruiting
Leukemia stem cell test for AML relapse in children
This study uses a special blood test (flow cytometry) to look for leukemia stem cells in your blood and bone marrow. The goal is to see if these cells can help predict if leukemia will come back after treatment, which might lead to better care for children and teens with AML.
Beijing, Beijing MunicipalityAges Up to 18 years - NCT06432465Recruiting
Brain stimulation to help prevent opioid relapse
This study uses a type of brain stimulation called tDCS (transcranial direct current stimulation) to see if it can help people who have recently started medication for opioid dependence (buprenorphine or methadone) stay on track and avoid relapse. The treatment is non-invasive and involves a mild electrical current applied to the scalp.
Providence, Rhode IslandAges 21–60 - NCT05751044RecruitingPhase 1/Phase 2
Study of four medicines for children with difficult blood cancers
This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.
ViennaAges 1–21 - NCT04162353RecruitingPhase 1
CAR cell therapy trial for multiple myeloma and related cancers
This early-phase (Phase 1) trial tests a lab-made immune-cell treatment that targets two markers, BCMA and CD19, in people whose cancer has not responded to standard options. It’s meant to see if the treatment is safe and how well it can work in these cancers.
Shenzhen, GuangdongAges Any age - NCT05962177Recruiting
Study of blood tests and scans in relapsing-remitting MS
This study follows adults with relapsing-remitting multiple sclerosis using MRI scans and blood tests. It aims to understand how the disease behaves and what markers in blood and imaging may relate to changes over time.
MontpellierAges 18–59 - NCT06392477RecruitingPhase 1
Testing a new drug for relapsed B-cell lymphoma
This trial tests an experimental drug, SAR448501/DR-0201, for people with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink tumors.
Camperdown, New South WalesAges 18 years+ - NCT06390930Recruiting
Breathing bursts of lower oxygen for hand function in MS
This study tests whether breathing short bursts of reduced oxygen (acute intermittent hypoxia) can improve hand function and nerve health in people with relapsing-remitting MS who have some hand weakness.
Chicago, IllinoisAges 18–75 - NCT06372717RecruitingPhase 1
Testing APL-4098 alone or combined for AML or MDS
This trial tests a new drug called APL-4098, given alone or with another medicine, for people with certain blood cancers (AML or MDS) that have come back or not responded to treatment. The goal is to see if it is safe and works well.
Clayton, VictoriaAges 18 years+ - NCT06366789RecruitingPhase 1
Testing a new drug for AML with FLT3 or spliceosome mutations
This trial tests a new drug called ZE46-0134 for adults with AML that has a specific gene change (FLT3 or spliceosome mutation) and hasn't been controlled by prior treatment. It aims to find the right dose and see if it can help stop the leukemia from growing.
Los Angeles, CaliforniaAges 18 years+ - NCT06378190RecruitingPhase 1/Phase 2
New CAR-T cell therapy for relapsed B-cell lymphoma
This trial tests a new type of CAR-T cell therapy (a treatment that uses your own immune cells to fight cancer) for people with B-cell lymphomas that have come back or not responded to standard treatments. It aims to see if this new manufacturing method is safe and effective.
Barcelona, BarcelonaAges 18–80 - NCT06377540RecruitingPhase 2
Pembrolizumab plus BEAM with stem cell transplant for Hodgkin lymphoma
This trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to the standard BEAM chemotherapy before a stem cell transplant can help people with relapsed Hodgkin lymphoma. It's for patients who are eligible for a transplant and have stable organ function.
Minneapolis, MinnesotaAges 18 years+ - NCT06356571RecruitingPhase 2
Isatuximab with carfilzomib and dexamethasone for multiple myeloma
This trial tests a new combination of drugs (isatuximab, carfilzomib, and dexamethasone) given as shots under the skin for people whose multiple myeloma has come back or stopped responding to treatment. It aims to see if this mix works better than previous options.
Phoenix, ArizonaAges 18 years+ - NCT06343311RecruitingPhase 1/Phase 2
T-cell therapy for adults with relapsed or refractory B-cell lymphoma
This trial tests a new T-cell therapy (EB103) for people with B-cell non-Hodgkin's lymphoma that has come back or stopped responding to treatment. It aims to see if the therapy is safe and effective.
Sacramento, CaliforniaAges 18 years+ - NCT06017518Recruiting
Watching local relapse after high-grade osteosarcoma treatment
This study is watching people whose high-grade osteosarcoma came back in the same bone area (local relapse) after treatment. It helps doctors understand how local relapse happens, so they can improve future care.
Bologna, BOAges Any age - NCT06343090Recruiting
Comparing two CAR T cell treatments for children and adults with B-ALL
This trial tests whether giving two types of CAR T cells (CD19 and CD22) one after the other works better than giving just one type (CD19) followed by a stem cell transplant for people whose B-cell acute lymphoblastic leukemia (B-ALL) has come back or not gone away. The goal is to see which approach offers a better chance of long-term remission.
Beijing, Beijing MunicipalityAges 1–70 - NCT06347068RecruitingPhase 1
CAR-T cell therapy for triple-negative breast cancer
This trial tests a new treatment using your own immune cells, modified to target a protein called B7-H3 on triple-negative breast cancer cells. It may help if other treatments haven't worked.
Chapel Hill, North CarolinaAges 18 years+ - NCT05794958RecruitingPhase 1
Safety of second CAR-T re-infusion for hard-to-treat lymphoma
This Phase 1 study tests whether a second re-infusion of axicabtagene ciloleucel (CAR-T) is safe in people with aggressive B-cell non-Hodgkin lymphoma that came back or did not respond after standard second-line CAR-T. It may help some patients by trying to improve disease control while carefully monitoring side effects.
Palo Alto, CaliforniaAges 18 years+ - NCT06326008RecruitingPhase 1
Donor immune cell therapy for leukemia that returned after treatment
This trial tests a two-step approach using donor immune cells to treat children with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments. First, a donor's CD19-targeted cells are given to bridge to a stem cell transplant, followed by CD22-targeted cells to prevent relapse.
Beijing, Beijing MunicipalityAges 1–18 - NCT05964829Recruiting
Test a leg sleeve to improve walking in multiple sclerosis
This trial studies whether using the Cionic “Neural Sleeve” can improve walking and leg movement in people with multiple sclerosis (MS). It may help if your MS affects mobility, and you can safely wear and tolerate the device during the day.
Cleveland, OhioAges 22–75 - NCT06297226RecruitingPhase 2
CAR T cell therapy for multiple myeloma
This trial tests a new CAR T cell therapy (arlocabtagene autoleucel) that targets a protein called GPRC5D on myeloma cells. It is for people whose multiple myeloma has come back or is not responding after trying at least four different types of treatment.
Birmingham, AlabamaAges 18 years+ - NCT06307054RecruitingPhase 1
CLL-1 CAR-NK cells for relapsed or refractory AML
This trial tests a therapy made from your own immune cells, engineered to target a marker called CLL-1 on leukemia cells, for people whose AML has come back or hasn't responded to standard treatments.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06292780RecruitingPhase 1/Phase 2
Testing linvoseltamab for AL amyloidosis that came back
This trial tests a new drug called linvoseltamab for people with AL amyloidosis that has returned or is not responding to treatment. It aims to see if the drug is safe and helps control the disease.
Duarte, CaliforniaAges 18 years+
Hear when a new Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapse?
- Yes. Clin2 currently lists 892 recruiting relapse studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapse trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapse trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.